Clinical Trials in a Dish.

Clinical trials 'in a dish' involve testing medical therapies for safety or effectiveness in the laboratory with human tissue. This has become possible owing to recent biotechnology advances including induced pluripotent stem cells, organs-on-a-chip, and whole-genome sequencing. We provide here an overview of the landscape and highlight steps the FDA is taking to advance the science of clinical trials in a dish and to support the development and validation of new regulatory paradigms to assess drug safety using these new technologies.

[1]  Vyas Ramanan,et al.  Modeling host interactions with hepatitis B virus using primary and induced pluripotent stem cell-derived hepatocellular systems , 2014, Proceedings of the National Academy of Sciences.

[2]  Sangeeta N. Bhatia,et al.  Human iPSC-Derived Hepatocyte-like Cells Support Plasmodium Liver-Stage Infection In Vitro , 2015, Stem cell reports.

[3]  K. Red-Horse,et al.  Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes as an In Vitro Model for Coxsackievirus B3–Induced Myocarditis and Antiviral Drug Screening Platform , 2014, Circulation research.

[4]  B. Strulovici,et al.  Induced pluripotent stem cells — opportunities for disease modelling and drug discovery , 2011, Nature Reviews Drug Discovery.

[5]  Dulciana D. Chan,et al.  Late sodium current block for drug‐induced long QT syndrome: Results from a prospective clinical trial , 2016, Clinical pharmacology and therapeutics.

[6]  T. Colatsky,et al.  The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative - Update on progress. , 2016, Journal of pharmacological and toxicological methods.

[7]  M. Kay,et al.  Genome editing of isogenic human induced pluripotent stem cells recapitulates long QT phenotype for drug testing. , 2014, Journal of the American College of Cardiology.

[8]  A K Capulli,et al.  Approaching the in vitro clinical trial: engineering organs on chips. , 2014, Lab on a chip.

[9]  Ruili Huang,et al.  Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen , 2016, Nature Medicine.

[10]  Russ B Altman,et al.  Human induced pluripotent stem cell–derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity , 2016, Nature Medicine.

[11]  U. Martin,et al.  Site-Specific Genome Engineering in Human Pluripotent Stem Cells , 2016, International journal of molecular sciences.